You are here: Industry Insights > PharmAbcine

News List

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020 prnasia
November 17, 2020
PharmAbcine Inc. announced that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.
PharmAbcine Partners with Samsung Biologics for PMC-403 contractpharma
September 22, 2020
The antibody is expected to enter a global ophthalmological clinical trial in 2022.
PharmAbcine Signs CMO Contract with Binex contractpharma
September 17, 2020
CDMO Binex to produce olinvacimab at its new 5,000L production line.
PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biotechnology (SLBio) to evaluate a combination therapy to treat NSCLC prnasia
August 04, 2020
PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a research collaboration with Wuxi Shuangliang Biotechnology (SLBio) to evaluate the combination of each party's clinical candidate, olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior b
PharmAbcine, SLBio Enter NSCLC Research Pact contractpharma
August 04, 2020
To evaluate olinvacimab and C-005, a 3rd generation of EGFR inhibitor with superior brain-blood-barrier permeability in treating non-small cell lung cancer.
PharmAbcine Enters Partnership with Thermo Fisher contractpharma
June 16, 2020
Will develop and manufacture Thermo Fisher’s immune checkpoint blockade, PMC-309 for Phase I.
Samsung Biologics, PharmAbcine Enter Antibody Pact contractpharma
April 07, 2020
To develop and manufacture PMC-402, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders.